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Background: This study aimed to investigate new bone formation using recombinant human bone morphogenetic
protein 2 (rhBMP-2) and locally applied bisphosphonate in rat calvarial defects.
Methods: Thirty-six rats were studied. Two circular 5 mm diameter bony defect were formed in the calvaria using a
trephine bur. The bony defect were grafted with Bio-Oss® only (group 1, n = 9), Bio-Oss® wetted with rhBMP-2 (group 2,
n = 9), Bio-Oss® wetted with rhBMP-2 and 1 mM alendronate (group 3, n = 9) and Bio-Oss® wetted with rhBMP-2 and
10 mM alendronate (group 4, n = 9). In each group, three animals were euthanized at 2, 4 and 8 weeks after surgery,
respectively. The specimens were then analyzed by histology, histomorphometry and immunohistochemistry analysis.
Results: There were significant decrease of bone formation area (p < 0.05) between group 4 and group 2, 3. Group 3
showed increase of new bone formation compared to group 2. In immunohistochemistry, collagen type I and
osteoprotegerin (OPG) didn’t show any difference. However, receptor activator of nuclear factor κB ligand (RANKL)
decreased with time dependent except group 4.
Conclusion: Low concentration bisphosphonate and rhBMP-2 have synergic effect on bone regeneration and this
is result from the decreased activity of RANKL of osteoblast.
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In oral and maxillofacial field, restoring bony defect and en-
hancing bone regeneration is one of the most interesting
subjects. Grafting bone materials such as autogenous,
allogenic, and heterogenous bone are most widely used to
restore bony defect. There have been studied to improve
the efficiency of the bone regeneration. In recent times,
there are reports of studies using growth factors (BMP,
PDGF, TGF-β, IGF etc.) to enhance the efficiency of such
bone grafting [1].
Bone morphogenetic protein (BMP) is one of the TGF-β
super family, known to form new bones and cartilage. It is
reported that BMP −2, −4, −5, −6, −7 etc. have been
revealed to have osseoinductibility [2–4]. Out of these,* Correspondence: ssh8080@pusan.ac.kr
†Equal contributors
1Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan
National University, 626-787 Yangsan, Mulgeum-eup, Korea
Full list of author information is available at the end of the article
© 2015 Kim et al. This is an Open Access article
(http://creativecommons.org/licenses/by/4.0), w
provided the original work is properly creditedrhBMP-2 which is obtained from recombinant DNA
technology from mammalian cells is known to stimulate
differentiation of osteoblast in cell experiments and to
induce osteogenesis in animal experiments [5–7].
Bisphosphonate is widely used in the treatment of osteo-
porosis and osseous metastasis of cancer, and it is known to
play a role of reducing bone loss by reducing or stopping
the function of osteoclast [8, 9]. As increased use of bis-
phosphonate, there have been reported bisphosphonate re-
lated osteonecrosis of jaw (BRONJ) due to suppressed
osteoclastogenesis [10, 11]. On the other hand, there are
studies regarding low concentration of locally applied bis-
phosphonate accelerates the healing of the tooth extraction
socket, bone fracture or increase the bone density of the
interface after titanium implant placement [12–14]. We hy-
pothesized that rhBMP-2 and low concentration bisphos-
phonate have synergic effect for bone regeneration. The
aim of this study was to investigate the combined effect ofdistributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
Fig. 1 Histological view at 2, 4 and 8 weeks. a 2 week group 1; b 2week group 2; c 2week group 3; d 2 week group 4; e 4 week group 1; f 4 week
group 2; g 4 week group 3; h 4 week group 4; i 8 week group 1; j 8 week group 2; k 8 week group 3; l 8 week group 4. (H-E stain, Magnification X 100)
Fig. 2 Inflammatory reaction of grafted site at 2 week. a Gross
specimen; b Group 1; c Group 2; d group 3; e Group 4. In group 4,
inflammatory cells and capillaries were observed. (H-E stain,
Magnification X 100)
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generation in a rat model.
Methods
Preparation of animal
Thirty-six Sprague-Dawley male rats (15 weeks old,
Koatech, INC. Korea) weighing between 250 g and 300
g comprised the animal experimental model used. The
animals were housed individually in standard rat cages
maintained under an ambient temperature of 24 °C to
26 °C and a 12/12 h light/dark cycle. The animals had
free access to drinking water and standard laboratory
pellets. This study was conducted at the Pusan National
University Institutional Animal Care and Use Committee
(PNU-2011-000254 ).
Experimental materials and surgical procedures
Each bony defect was stuffed by Bio-Oss®, inorganic bovine
bone, as xenograft material. rhBMP-2 was produced in
E. coli using genetic engineering (Cowellmedi Co, Busan,
Korea). As for rhBMP-2, 100 μg/1 mL concentrations were
used. Alendronate (Sigma, St. Louis, MO, USA) was used
as bisphosphonate. 1 mM (low concentration) and 10 mM
(high concentration) alendronate were conducted this
study.
The animals were anesthetized with a mixture of
10 mg/kg of xylazine hydrochloride (Rumpun® Bayer,
Korea) and 100 mg/kg of ketamine chloride (Ketalar®,
Yuhan Corporation, Korea). The dorsal area of the rat
cranium was shaved before surgery, and the surgical
field was prepared with an iodine solution. A midline
skin incision was performed on the skull, and the perios-
teum with the temporalis muscle was reflected laterally.
Two symmetrical round 5 mm diameter bony defects werethen formed in the calvaria using 5 mm diameter trephine
(Hee Sung Corp., Seoul, Korea). The bony defect were
grafted with Bio-Oss® only (group 1, n = 9), Bio-Oss® wetted
with rhBMP-2 (group 2, n = 9), Bio-Oss® wetted with
rhBMP-2 and 1 mM alendronate (group 3, n = 9) and Bio-
Oss® wetted with rhBMP-2 and 10 mM alendronate (group
4, n = 9). Then, the muscle layer was closed with 4–0
Vicryl® sutures in a continuous fashion, and the skin
Table 1 Inflammatory reaction in each group
Time Group 1 Group 2 Group 3 Group 4
2 week ± ± ± +
(±; minimal, +; mild)
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injected for prevention of infection after surgery. The
animals from each group were sacrificed at 2, 4 and 8
weeks after surgery. The skin was dissected, the calvaria
harvested and immediately immersed in a 10 % tem-
pered solution of formaldehyde.Histology
Each specimen was fixed in 10 % formaldehyde solution,
decalcified in formic acid for 48 h, and embedded in paraf-
fin. Serial cross-sections (5 μm) were cut through the larger
diameter of the defect and stained with hematoxylin-eosin
(H-E). The H-E stains reveal the cellular reactions indicat-
ing bone formation. The slides were photographed with the
use of a virtual slide system (Scanscope CS system, Aperio
Technologies, Vista,CA).Histomorphometric analysis
The Aperio Technologies Scanscope CS system is use-
ful for calculating new bone formation areas on H-E
stained slides. The calculation, involving just the draw-
ing of the newly formed bone outlines, is easily done.
Slides in each group were scanned by virtual slide sys-
tem microscopy (X100), and then 2 slides from each
group were selected in the 2, 4, 8 weeks. To calculate
the new bone formation area, 4 sites were randomly se-
lected for each slide, the photographs of which were
0.600 mm × 0.500 mm. In this study, we applied 2 statis-
tical methods to the significance testing of each group.
The dependent variables of the control and experimen-
tal groups were averages and standard deviations. The
difference of the dependent variables in each group for
the 2, 4, 8 weeks was analyzed by Kruskal-Wallis test
and Tukey’s post hoc test. The collected data wereFig. 3 Measurement of bone formation area by Aperio imaging scope. New
formed bone. H-E stain, Magnification X 100analyzed with the use of SPSS 18.0 software (SPSS Inc.,
Chicago, IL, USA).Immunohistochemical analysis
The 5 μm thick slice maintained at 60 °C in an oven for
an hour. After that, the sample was washed with dis-
tilled water after being hydrated using several steps of
alcohol after the paraffin was removed. This treatment
was repeated four times for five minutes with xylene.
And then the sample was washed three times with the
buffer solution for three minutes. In order to remove
the intrinsic peroxide within the tissue, the sample was
reacted with 0.3 % H2O2 solution. The sample was
washed four times with buffer solution in order to in-
hibit the unusual combination within the tissue, after
reacting with blocking serum (goat ImmunoCruz stain-
ing system, Santa Cruz Biotechnology, Inc., USA) for
an hour, and reacting for a night with a dilution of each
primary antibody, OPG, RANKL, Collagen type I (Santa
Cruz biotechnology, OPG 1:120, RANKL 1:40, collagen
type I 1:100). After being washed with the buffer solu-
tion, the sample was reacted with a secondary antibody
labeled Biotin for an hour, washed four times again
with the buffer solution, and reacted with the enzyme
conjugate streptavidin (goat immunocruz staining sys-
tem, Santa Cruz Biotechnology) for an hour at room
temperature.
The tissue section was again washed in PBS three
times for 10 min and was colored for 3 min in a solu-
tion mixed with diaminobenzidine chromogen and
hydrogen peroxidase. The section was then washed in
Tris buffer, PBS and distilled water for 10 min each. After
that, it was counterstained with Harris hematoxylin and
then mounted.
After each staining we evaluated the slides by immu-
nohistochemical reactivity for RANKL using a scoring
system of −, +, ++, and +++, which corresponded to ab-
sent staining, weak staining (<25 % of cells), moderate
staining (<50 % of cells), and strong staining (>50 %),
respectively. In the evaulation of OPG, collagen Type Ibone formation can be calculated just drawing the outlines of newly
Table 3 Post hoc test results (Tukey HSD)
P value
Groups 2 week 4 week
Group 1 Group 2 0.014* 0.182
Group 3 0.003* 0.003*
Group 4 0.681 0.661
Group 2 Group 3 0.636 0.067
Group 4 0.065 0.765
Group 3 Group 4 0.012* 0.020*
(*P < 0.05)
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After grafting, at 2 week collagen fiber arrangement was
finding in all group. Osteoblast proliferation was ob-
served that occurred in early stage of new bone forma-
tion . At 4 week, relatively small bone formation was
observed at group 2, 3, 4. At 8 week, all group showed
the aspect of complete mineralization (Fig. 1).
Degrees of inflammatory reaction
Relative inflammatory reaction intensity was evaluated
for each groups. We examined the specimens at 2 week
in each group because most of healing process and in-
flammatory phase are almost finished within 2 week. In
group 1, 2, 3, any remarkable inflammatory reaction was
not observed, but mild inflammation was observed in
group 4 (Fig. 2, Table 1).
Histomorphometric analysis
After measuring the area where bones were formed by
randomly designating 4 locations from one specimen, an
average was calculated and shown by ratio. The width of
the designated rectangle was set to 0.3 mm [2] (Fig. 3).
In 2 weeks, mean extent of bone formation was
10.46 % in group 1, 17.63 % in group 2, 19.73 % in group
3 and 12.41 % in group 4. In 4 weeks, that was 18.79 %
in group 1, 23.21 % in group 2, 28.49 % in group 3 and
21.27 % in group 4. In 8 weeks, the extent was 31.93 %
in group 1, 34.55 % in group 2, 38.98 % in group 3 and
30.68 % in group 4.
The bone formation area was calculated from bone for-
mation ratio and expressed as mean ± standard deviation.
In 2, 4 week, there exist significant difference among each
groups. In 8 week there were not any difference among
groups. In 2 week, group 2 and 3 showed increased bone
formation significantly compared to group 1. And group 3
increased larger than group 4 significantly. In 4 week, group
3 showed increased bone formation area compred to group
1 and 4 (Tables 2 and 3).Table 2 Measurement of bone formation area
Time Group 1 Group 2 Group 3 Group 4 P value



























(Unit ; mm2, *p < 0.05)Immunohistochemistric finding
Collagen type I
With regard to collagen, high expression was examined
in group 1,2,3. There was no difference among three
groups, but group 4 shows less expression of collagen
type I relatively than other group (Fig. 4, Table 4).
OPG
In the analysis of OPG expression, it shows moderate
expression at 2, 4 weeks, and decrease at 8 weeks. Like
collagen type I, no differeces were examed among group
1,2,3. In group 4, OPG did not manifest well (Fig. 5,
Table 4).
RANKL
In the case of RANKL, expression of RANKL was de-
creased with time dependant except group 4. Manifest-
ation seems to be slightly reduced in the 2 and 4 week
stages in group 3. It continues to be manifested moder-
ate in group 4 (Fig. 6, Table 4).
Discussion
In this study we aimed to investigate if rhBMP-2 and locally
applied bisphosphonate have synergic effect on bone regen-
eration. Since Urist reported the osteoconductive potential
of BMP 2, numerous studies were conducted on rhBMP-2
[2]. Active studies are being carried out after it was ap-
proved for use in dental field by the FDA (INFUSE® Bone
Graft, Medtronic Spinal and Biologics, Memphis, Tenn) in
2007. BMP-2 have an effect on precursor cells like mesen-
chymal stem cells which differentiating into osteoblast. It is
widely known that BMP, when local applied, accelerates
bone regeneration [15].
Phamacologic mechanism of alendronate is inhibition of
farnesyl diphosphate synthase in the mevalonate pathway
essential for the prenylation of proteins in osteoclasts. This
causes mechanical inhibition of osteoclast adhesion on the
bone margin and osteoclast apoptosis [16]. The effect of
BPs on osteoclasts could also be produced by osteoblasts.
Osteoblast/stromal cells regulate osteoclastogenesis by
M-CSF, RANKL and OPG [17, 18]. Through cell-to-cell
contact of osteoblast/stromal cells with osteoclasts, RANKL
Fig. 4 Collagen type I antibody reaction of grafted sites. a 2 week group 1; b 2week group 2; c 2week group 3; d 2 week group 4; e 4 week group 1; f 4
week group 2; g 4 week group 3; h 4 week group 4; i 8 week group 1; j 8 week group 2; k 8 week group 3; l 8 week group 4. Magnification X 100
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entiate into osteoclasts. There are reports that low con-
centration bisphosphonate stimulate the proliferation
and differentiation of osteoblast [19–22]. Also systemic
or local short period application of bisphosphonate im-
proves bone regeneration due to pharmacological ef-
fects in vivo [23–26].
In the histomorphometry analysis, in the 2 week, signifi-
cant difference was observed in group 2 and 3 compared
to the group 1 and 4. In spite of group 2 was much bone
formation, there was not significant difference between
group 2 and 3. In the results of the 4 week, group 3 was
only significant difference compare to other group and
highest bone formation. It seems ordinary BMP was in-





Group 1 Group 2 Group 3 Group 4
Collagen type I 2 ++ +++ +++ +
4 ++ ++ ++ ++
8 +++ +++ +++ +
2 ++ ++ ++ +
OPG 4 +/++ ++ +/++ +
8 ++ ++ +++ +
2 ++ ++ + ++
RANKL 4 ++ +++ −/+ ++
8 + + + ++
(−; no immunoreactivity, +; weak immunoactivity, ++; moderate immunoactivity,
+++; strong immunoactivity, Abbreviations: OPG osteoprotegerin, RANKL receptor
activator nuclear factor κB ligand)main role in bone formation on 2 week. In 4 and 8 weeks
there was more bone formation in group 3. It seems alen-
dronate was main role in suppression of osteoclastic activ-
ity at initiate of bone remodeling with BMP.
RANKL is known as osteoclast differentiation factor
and it is known to accelerate and stimulate their differ-
entiation [27]. The manifestation of RANKL appears on
the surface of marrow stromal cells, immature osteo-
blasts or mesenchymal cells [28]. OPG is an important
regulator of osteoclastogenesis via it’s binding to RANKL
of the effects of RANKL. OPG is role of inhibiting bone
resorption. When its concentration is reduced, the re-
sorption processes may prevail and bone loss occurs
[29, 30]. In the immunohistochemistry findings, in the
case of collagen, most came out uniformly without a sig-
nificant difference in most of the specimen, but because
osteogenesis occurred relatively not well in group 4, it
seems collagen manifestation also did not appear well.
Likewise, even in the case of OPG, it seems to be not
manifested well because of a relatively weak of osteogen-
esis in the high concentration group. In the case of
RANKL, it seems there is a slight reduction in manifest-
ation from the group 3 in the early phase, and this seems
to show a suppression of the osteoclastic activity of alen-
dronate. In group 4, RANKL continues to be moderate
manifested, this is seems to be relatively less bone for-
matinon and suppression of osteoclastic activity a weak
of osteogenesis, though its mechanism is vague.
Unlike previous experiments, this experiment was de-
signed in combination with elements that can be easily ap-
plied to preclinical practice. First, as scaffolds or carrier, it
has used deproteinized bovine bone, and was not applied
by adsorbing alendronate for a long period of time, and dir-
ect used 1 mM, 10 mM together with rhBMP-2. And this
Fig. 5 OPG antibody reaction of grafted sites. a 2 week group 1; b 2week group 2; c 2week group 3; d 2 week group 4; e 4 week group 1; f 4 week
group 2; g 4 week group 3; h 4 week group 4; i 8 week group 1; j 8 week group 2; k 8 week group 3; l 8 week group 4. Magnification X 100
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BMP and bisphosphonate together. The concentration of
BMP was determined from the manufacturer, and the con-
centration of bisphosphonate is known to use a concentra-
tion of 1 mg/ml in many theses, but it was difficult to find
grounds for these. Therefore, we used the concentration of
1 mM/ml (0.325 mg/ml) that was suggested purpose of
prevent root resorption in the delayed replantation of an
extracted tooth as a standard [31–33]. In group 3, there
were statistically significant differences in 2 and 4 week
compared to group 1 and 4. It seems there is a great bone
forming effect since it showed a significant difference in the
4th week compared to group 2. While it is difficult to pro-
vide an accurate interpretation of its mechanism since theseFig. 6 RANKL antibody reaction of grafted sites. a 2 week group 1; b 2week gr
group 2; g 4 week group 3; h 4 week group 4; i 8 week group 1; j 8 week grouare not results from substituting one condition but from
using compositive methods, the group using a combination
of a rhBMP-2 and 1 mM of alendronate seems to have fas-
ter and better bone formation than the control group.
Conclusion
This study was conducted to investigate whether alen-
dronate and rhBMP-2 have combined effect on bone re-
generation. Our results indicate that low concentration
bisphosphonate and rhBMP-2 have synergic effect on
bone regeneration and this is result from the decreased
activity of RANKL of osteoblast. Though further studies
are needed to find out an appropriate concentration, it
seems capable of being clinically applied in bony defect.oup 2; c 2week group 3; d 2 week group 4; e 4 week group 1; f 4 week
p 2; k 8 week group 3; l 8 week group 4. Magnification X 100
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